Sweetly O\u27er My Senses Stealing

Sweetly o\u27er my senses stealing,Fancied pleasures round me rollWhile hope its balmy joys its joys revealing,Sheds its influence o\u27er my soul!Lightly beats lightly beats the heart that never Felt the pangs felt the pangs that wait on loveSadly sighs sadly sighs the breast that everbarter\u27d peace its joys to prove. Hapless mind doom\u27d forever to mournThe sweet peace that can never return The peace that can never return ,Lightly beats lightly beats the heart that neverFelt the pangs felt the pangs that wait on love,Sadly sighs sadly sighs the breast that everBarter\u27d peace its joys to prove,Barter\u27d peace its joys to proveLightly beats lightly beats the heart that never Felt the pangs felt the pangs that wait on love,Sadly sighs the heart that ever barter\u27d peace its joys to prove

Il bilancio integrato per le PMI

Accanto ai capitali finanziario e produttivo, ogni impresa fonda il proprio business e il proprio successo anche su risorse intangibili, quali il capitale intellettuale, il capitale umano, il capitale sociale e relazionale ed il capitale naturale. Il tradizionale bilancio economico-finanziario, però, non è adatto a valutare e rappresentare tali risorse, poiché è stato concepito con riferimento ad un’economia industriale fondata pressoché esclusivamente su capitali tangibili; pertanto, anche avuto riguardo alla realtà delle PMI, si rende oggi necessario introdurre nuovi strumenti e nuovi indicatori per la misurazione e la rendicontazione, che siano in grado di cogliere e valorizzare anche le componenti immateriali del capitale aziendale. In questo contesto, il bilancio integrato si pone come una forma evoluta di comunicazione aziendale, finalizzata ad illustrare come strategia, governance, modello di business, rapporti con gli stakeholder, performance passate e prospettive future, rischi e opportunità consentano anche ad un’impresa di piccole e medie dimensioni di creare valore nel breve, medio e lungo termine

Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis

Importance: Meropenem is a widely prescribed β-lactam antibiotic. Meropenem exhibits maximum pharmacodynamic efficacy when given by continuous infusion to deliver constant drug levels above the minimal inhibitory concentration. Compared with intermittent administration, continuous administration of meropenem may improve clinical outcomes. Objective: To determine whether continuous administration of meropenem reduces a composite of mortality and emergence of pandrug-resistant or extensively drug-resistant bacteria compared with intermittent administration in critically ill patients with sepsis. Design, setting, and participants: A double-blind, randomized clinical trial enrolling critically ill patients with sepsis or septic shock who had been prescribed meropenem by their treating clinicians at 31 intensive care units of 26 hospitals in 4 countries (Croatia, Italy, Kazakhstan, and Russia). Patients were enrolled between June 5, 2018, and August 9, 2022, and the final 90-day follow-up was completed in November 2022. Interventions: Patients were randomized to receive an equal dose of the antibiotic meropenem by either continuous administration (n = 303) or intermittent administration (n = 304). Main outcomes and measures: The primary outcome was a composite of all-cause mortality and emergence of pandrug-resistant or extensively drug-resistant bacteria at day 28. There were 4 secondary outcomes, including days alive and free from antibiotics at day 28, days alive and free from the intensive care unit at day 28, and all-cause mortality at day 90. Seizures, allergic reactions, and mortality were recorded as adverse events. Results: All 607 patients (mean age, 64 [SD, 15] years; 203 were women [33%]) were included in the measurement of the 28-day primary outcome and completed the 90-day mortality follow-up. The majority (369 patients, 61%) had septic shock. The median time from hospital admission to randomization was 9 days (IQR, 3-17 days) and the median duration of meropenem therapy was 11 days (IQR, 6-17 days). Only 1 crossover event was recorded. The primary outcome occurred in 142 patients (47%) in the continuous administration group and in 149 patients (49%) in the intermittent administration group (relative risk, 0.96 [95% CI, 0.81-1.13], P = .60). Of the 4 secondary outcomes, none was statistically significant. No adverse events of seizures or allergic reactions related to the study drug were reported. At 90 days, mortality was 42% both in the continuous administration group (127 of 303 patients) and in the intermittent administration group (127 of 304 patients). Conclusions and relevance: In critically ill patients with sepsis, compared with intermittent administration, the continuous administration of meropenem did not improve the composite outcome of mortality and emergence of pandrug-resistant or extensively drug-resistant bacteria at day 28. Trial registration: ClinicalTrials.gov Identifier: NCT03452839

Vocabolario della lingua italiana

A frequently put forward argument claims that biological systems are too complex for mathematical methods to be fruitfully applied. I argue that this argument from complexity is a fallacy. To the contrary, it is exactly the complexity of biological systems which calls for the use of mathematical methods. While some research strategies in molecular biology used to be less accessible for mathematical analysis, the emergence of systems biology as a scientific discipline is the most recent example of successful and effective applications of mathematical methods in biology. In today’s scientific practice, there is evidence for the "unreasonable effectiveness of mathematics" in biology, differing from traditional mathematical biology, thus giving new support to a notion that still cannot be taken for granted

Giulietta e Romeo. Excerpts. Arr - Don Mus.Ms. 2082 : winds

Nicola Antonio ZingarelliQuelle: manuscript. - Provenienz: Fürstlich Fürstenbergische Hofbibliothek, DonaueschingenGiulietta e Romeo | Del Sig Zingarell

Giulietta e Romeo. Excerpts - Don Mus.Ms. 2185 : S, vl, b

Nicola Antonio ZingarelliQuelle: manuscript. - Provenienz: Fürstlich Fürstenbergische Hofbibliothek, DonaueschingenGiulietta e Romeo | Scena e Rondo | del | Signore Zingarelli | Pr: 36 X